133 related articles for article (PubMed ID: 37385955)
21. Effect of dapagliflozin on urinary albumin excretion in patients with chronic kidney disease with and without type 2 diabetes: a prespecified analysis from the DAPA-CKD trial.
Jongs N; Greene T; Chertow GM; McMurray JJV; Langkilde AM; Correa-Rotter R; Rossing P; Sjöström CD; Stefansson BV; Toto RD; Wheeler DC; Heerspink HJL;
Lancet Diabetes Endocrinol; 2021 Nov; 9(11):755-766. PubMed ID: 34619106
[TBL] [Abstract][Full Text] [Related]
22. Effects of canagliflozin on anaemia in patients with type 2 diabetes and chronic kidney disease: a post-hoc analysis from the CREDENCE trial.
Oshima M; Neuen BL; Jardine MJ; Bakris G; Edwards R; Levin A; Mahaffey KW; Neal B; Pollock C; Rosenthal N; Wada T; Wheeler DC; Perkovic V; Heerspink HJL
Lancet Diabetes Endocrinol; 2020 Nov; 8(11):903-914. PubMed ID: 33065060
[TBL] [Abstract][Full Text] [Related]
23. Clinical Utility of KidneyIntelX in Early Stages of Diabetic Kidney Disease in the CANVAS Trial.
Lam D; Nadkarni GN; Mosoyan G; Neal B; Mahaffey KW; Rosenthal N; Hansen MK; Heerspink HJL; Fleming F; Coca SG
Am J Nephrol; 2022; 53(1):21-31. PubMed ID: 35016188
[TBL] [Abstract][Full Text] [Related]
24. Effect of Dapagliflozin on Cardiovascular Outcomes According to Baseline Kidney Function and Albuminuria Status in Patients With Type 2 Diabetes: A Prespecified Secondary Analysis of a Randomized Clinical Trial.
Zelniker TA; Raz I; Mosenzon O; Dwyer JP; Heerspink HHJL; Cahn A; Goodrich EL; Im K; Bhatt DL; Leiter LA; McGuire DK; Wilding JPH; Gause-Nilsson I; Langkilde AM; Sabatine MS; Wiviott SD
JAMA Cardiol; 2021 Jul; 6(7):801-810. PubMed ID: 33851953
[TBL] [Abstract][Full Text] [Related]
25. Mediators of the Effects of Canagliflozin on Heart Failure in Patients With Type 2 Diabetes.
Li J; Woodward M; Perkovic V; Figtree GA; Heerspink HJL; Mahaffey KW; de Zeeuw D; Vercruysse F; Shaw W; Matthews DR; Neal B
JACC Heart Fail; 2020 Jan; 8(1):57-66. PubMed ID: 31676303
[TBL] [Abstract][Full Text] [Related]
26. Effect of canagliflozin in non-diabetic obese patients with albuminuria: A randomized, double-blind, placebo-controlled trial.
Greeviroj P; Puapatanakul P; Phannajit J; Takkavatakarn K; Kittanamongkolchai W; Boonchaya-Anant P; Katavetin P; Praditpornsilpa K; Eiam-Ong S; Susantitaphong P
Clin Nephrol; 2023 Nov; 100(5):224-230. PubMed ID: 37675488
[TBL] [Abstract][Full Text] [Related]
27. Canagliflozin and Kidney-Related Adverse Events in Type 2 Diabetes and CKD: Findings From the Randomized CREDENCE Trial.
Heerspink HJL; Oshima M; Zhang H; Li J; Agarwal R; Capuano G; Charytan DM; Craig J; de Zeeuw D; Di Tanna GL; Levin A; Neal B; Perkovic V; Wheeler DC; Yavin Y; Jardine MJ
Am J Kidney Dis; 2022 Feb; 79(2):244-256.e1. PubMed ID: 34029680
[TBL] [Abstract][Full Text] [Related]
28. Impact of Canagliflozin on Kidney and Cardiovascular Outcomes by Type 2 Diabetes Duration: A Pooled Analysis of the CANVAS Program and CREDENCE Trials.
Tobe SW; Mavrakanas TA; Bajaj HS; Levin A; Tangri N; Slee A; Neuen BL; Perkovic V; Mahaffey KW; Rapattoni W; Ang FG
Diabetes Care; 2024 Mar; 47(3):501-507. PubMed ID: 38252809
[TBL] [Abstract][Full Text] [Related]
29. Cardiorenal Biomarkers, Canagliflozin, and Outcomes in Diabetic Kidney Disease: The CREDENCE Trial.
Januzzi JL; Mohebi R; Liu Y; Sattar N; Heerspink HJL; Tefera E; Vaduganathan M; Butler J; Yavin Y; Li J; Pollock CA; Perkovic V; Neal B; Hansen MK
Circulation; 2023 Aug; 148(8):651-660. PubMed ID: 37603600
[TBL] [Abstract][Full Text] [Related]
30. Primary and Secondary Cardiovascular and Kidney Prevention With Canagliflozin: Insights From the CANVAS Program and CREDENCE Trial.
Sharma A; Razaghizad A; Joury A; Levin A; Bajaj HS; Mancini GBJ; Wong NC; Slee A; Ang FG; Rapattoni W; Neuen BL; Arnott C; Perkovic V; Mahaffey KW
J Am Heart Assoc; 2024 Feb; 13(3):e031586. PubMed ID: 38240199
[TBL] [Abstract][Full Text] [Related]
31. Rationale, design and baseline characteristics of the CANagliflozin cardioVascular Assessment Study-Renal (CANVAS-R): A randomized, placebo-controlled trial.
Neal B; Perkovic V; Matthews DR; Mahaffey KW; Fulcher G; Meininger G; Erondu N; Desai M; Shaw W; Vercruysse F; Yee J; Deng H; de Zeeuw D;
Diabetes Obes Metab; 2017 Mar; 19(3):387-393. PubMed ID: 28120497
[TBL] [Abstract][Full Text] [Related]
32. Sodium-glucose cotransporter 2 inhibitors: renal outcomes according to baseline albuminuria.
Delanaye P; Wissing KM; Scheen AJ
Clin Kidney J; 2021 Dec; 14(12):2463-2471. PubMed ID: 34950459
[TBL] [Abstract][Full Text] [Related]
33. The Effect of Atrasentan on Kidney and Heart Failure Outcomes by Baseline Albuminuria and Kidney Function: A
Waijer SW; Gansevoort RT; Bakris GL; Correa-Rotter R; Hou FF; Kohan DE; Kitzman DW; Makino H; McMurray JJV; Perkovic V; Tobe S; Parving HH; de Zeeuw D; Heerspink HJL
Clin J Am Soc Nephrol; 2021 Dec; 16(12):1824-1832. PubMed ID: 34853062
[TBL] [Abstract][Full Text] [Related]
34. Rationale and study design of a randomized controlled trial to investigate the renoprotective effect of canagliflozin assessed by test of renal hemodynamics in diabetic kidney disease (the FAGOTTO study).
Kato S; Kuwatsuka Y; Ando M; Tatematsu Y; Nishibori N; Maruyama S
BMC Nephrol; 2023 Aug; 24(1):228. PubMed ID: 37537531
[TBL] [Abstract][Full Text] [Related]
35. Different eGFR Decline Thresholds and Renal Effects of Canagliflozin: Data from the CANVAS Program.
Oshima M; Neal B; Toyama T; Ohkuma T; Li Q; de Zeeuw D; Heerspink HJL; Mahaffey KW; Fulcher G; Canovatchel W; Matthews DR; Perkovic V
J Am Soc Nephrol; 2020 Oct; 31(10):2446-2456. PubMed ID: 32694216
[TBL] [Abstract][Full Text] [Related]
36. Canagliflozin Slows Progression of Renal Function Decline Independently of Glycemic Effects.
Heerspink HJ; Desai M; Jardine M; Balis D; Meininger G; Perkovic V
J Am Soc Nephrol; 2017 Jan; 28(1):368-375. PubMed ID: 27539604
[TBL] [Abstract][Full Text] [Related]
37. Effect of SGLT2 Inhibitors on Stroke and Atrial Fibrillation in Diabetic Kidney Disease: Results From the CREDENCE Trial and Meta-Analysis.
Zhou Z; Jardine MJ; Li Q; Neuen BL; Cannon CP; de Zeeuw D; Edwards R; Levin A; Mahaffey KW; Perkovic V; Neal B; Lindley RI;
Stroke; 2021 May; 52(5):1545-1556. PubMed ID: 33874750
[TBL] [Abstract][Full Text] [Related]
38. Short-Term Changes in Albuminuria and Risk of Cardiovascular and Renal Outcomes in Type 2 Diabetes Mellitus: A Post Hoc Analysis of the EMPA-REG OUTCOME Trial.
Waijer SW; Xie D; Inzucchi SE; Zinman B; Koitka-Weber A; Mattheus M; von Eynatten M; Inker LA; Wanner C; Heerspink HJL
J Am Heart Assoc; 2020 Sep; 9(18):e016976. PubMed ID: 32893717
[TBL] [Abstract][Full Text] [Related]
39. Rationale, design and baseline characteristics of the effect of canagliflozin in patients with type 2 diabetes and microalbuminuria in the Japanese population: The CANPIONE study.
Miyamoto S; Heerspink HJL; de Zeeuw D; Toyoda M; Suzuki D; Hatanaka T; Nakamura T; Kamei S; Murao S; Hida K; Ando S; Akai H; Takahashi Y; Koya D; Kitada M; Sugano H; Nunoue T; Nakamura A; Sasaki M; Nakatou T; Fujimoto K; Kawanami D; Wada T; Miyatake N; Yoshida M; Shikata K;
Diabetes Obes Metab; 2022 Aug; 24(8):1429-1438. PubMed ID: 35491532
[TBL] [Abstract][Full Text] [Related]
40. Blood Pressure Effects of Canagliflozin and Clinical Outcomes in Type 2 Diabetes and Chronic Kidney Disease: Insights From the CREDENCE Trial.
Ye N; Jardine MJ; Oshima M; Hockham C; Heerspink HJL; Agarwal R; Bakris G; Schutte AE; Arnott C; Chang TI; Górriz JL; Cannon CP; Charytan DM; de Zeeuw D; Levin A; Mahaffey KW; Neal B; Pollock C; Wheeler DC; Luca Di Tanna G; Cheng H; Perkovic V; Neuen BL
Circulation; 2021 May; 143(18):1735-1749. PubMed ID: 33554616
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]